lifestyle.tweeternet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
April 28, 2026
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
April 28, 2026
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
April 27, 2026
Santhera Appoints Orlando Oliveira as Chief Executive Officer
April 23, 2026
Full Year 2025 Trading Update
March 12, 2026
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
March 10, 2026
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy
March 9, 2026
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
February 27, 2026
Santhera Appoints Stifel as Corporate Finance Advisor
February 12, 2026